Physiogenex will be presenting radiotracer-based hyperinsulinemic euglycemic clamp studies and diabetic nephropathy models at the World Congress of Insulin Resistance (WCIR) 2018, in Los Angeles, CA, USA, November 29th – December 1st, 2018. The abstracts will be...
Physiogenex will be presenting the effects of green coffee and green tea at the Obesity Week 2018, in Nashville, TN, USA, November 11-15th, 2018. The study will be presented by Dr. François Briand, Director of Research and Business Development, during the poster...
Physiogenex will be presenting its 3-week ultra-fast NASH screening mouse model mouse at the Liver Meeting 2018, in San Francisco, November 9th-13th, 2018. The effects of GLP-1 receptor agonists in this innovative NASH mouse model will be presented by Dr. François...
Physiogenex will be presenting its innovative animal models of diabetic nephropathy, namely the db/db mouse on high protein diet and the Unx/salt supplemented SDT fatty rat, at the ASN Kidney Week 2018, in San Diego, California. The studies, performed by Physiogenex...
Physiogenex will be presenting a hyperinsulinemic euglycemic clamp study differentiating insulin analogues in STZ-rats, a model of experimental diabetes. The study will be presented by Dr. François Briand, Director of Research and Business Development, during the...
Physiogenex will be presenting a study dealing with the effects of obeticholic acid and elafibranor in various animal models of NASH/hepatic fibrosis. The study will be presented by Dr. François Briand, Director of Research and Business Development, during the poster...
